London, Ontario, Canada and Kiel, Germany / October 23, 2024: Today the Canadian company Diagnostics Biochem Canada, Inc. (DBC) and the German company Demeditec agreed on a strategical partnership focused on the distribution of DBC’s unique portfolio of ELISA products. The goal of this cooperation is to combine the strengths of both companies for the expanded supply of high-quality ELISAs to many territorial regions worldwide, further expanding DBC’s global reach through Demeditec’s well established distribution network. DBC’s portfolio includes a comprehensive menu of Endocrinology based analytes (e.g. steroids, hormones, and metabolic markers) as well as more specialized niche diagnostic markers such as Vasoactive Intestinal Polypeptide (VIP), Plasma Renin Activity and Total Estrogen.  The expanded collaboration strengthens both companies with respect to the ongoing challenges of the new IVDR regulations.